Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Sucampo Pharmaceuticals, Inc.    SCMP

News SummaryMost relevantAll newsSector newsTweets

Sucampo Pharmaceuticals, Inc. : Sucampo Pharmaceuticals Announces Second Quarter and Six Months 2013 Results and Operating Highlights Teleconference and Webcast

share with twitter share with LinkedIn share with facebook
share via e-mail
07/25/2013 | 01:40pm CEST
Sucampo Pharmaceuticals Announces Second Quarter and Six Months 2013 Results and Operating Highlights Teleconference and Webcast

BETHESDA, Md., July 25, 2013 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) ("Sucampo"), a global biopharmaceutical company, today announced that it will host a webcast and teleconference with senior management to discuss its financial results and operating highlights for the second quarter and six months ended June 30, 2013, on Thursday, August 8, 2013, at 5:00 pm Eastern. The press release announcing the financial results and operating highlights is expected to be released after the close of the capital markets that day.

Investors interested in accessing the live audio webcast of the teleconference may do so at http://investor.sucampo.com/phoenix.zhtml?c=201197&p=irol-calendar and should log on 10 to 15 minutes before the teleconference begins in order to download any software required. Presentation slides will be available via the webcast link. A replay of the webcast will also be available on Sucampo's website for several days after the live event. Alternatively, investors may dial 800-901-5241 (domestic) or 617-786-2963 (international) and use passcode 92414824. A replay of the teleconference will be available by dialing 888-286-8010 (domestic) or 617-801-6888, passcode 49458753, approximately two hours after the teleconference concludes. The archive of the teleconference will remain available for 30 days.

About Sucampo Pharmaceuticals, Inc.

Sucampo Pharmaceuticals, Inc. is a global biopharmaceutical company focused on innovative research, discovery, development and commercialization of proprietary drugs based on prostones. The therapeutic potential of prostones was first discovered by Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo's Chairman, Chief Executive Officer, Chief Scientific Officer, and co-founder. Prostones, naturally occurring fatty acid metabolites that have emerged as promising compounds with unique physiological activities, can be targeted for the treatment of unmet or underserved medical needs. For more information, please visit www.sucampo.com.

Sucampo Forward-Looking Statement

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, future financial and operating results, and other statements that are not historical facts. The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the impact of pharmaceutical industry regulation and health care legislation; Sucampo's ability to accurately predict future market conditions; dependence on the effectiveness of Sucampo's patents and other protections for innovative products; the risk of new and changing regulation and health policies in the U.S. and internationally and the exposure to litigation and/or regulatory actions. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Sucampo undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this presentation should be evaluated together with the many uncertainties that affect Sucampo's business, particularly those mentioned in the risk factors and cautionary statements in Sucampo's most recent Form 8-K and 10-K, which Sucampo incorporates by reference.

CONTACT: Sucampo Pharmaceuticals, Inc.
         Silvia Taylor
         Senior Vice President, IR, PR and Corporate Communications
Sucampo Pharmaceuticals, Inc.
distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
08/11 SUCAMPO PHARMACEUTICALS : Study Results Published in The Lancet Demonstrate Safe..
08/07 SUCAMPO PHARMACEUTICALS : Drug Makers Stock Performance Review -- DURECT, Sucamp..
08/02 SUCAMPO PHARMACEUTICALS : reports 2Q loss
08/02 SUCAMPO PHARMACEUTICALS : Management's Discussion and Analysis of Financial Cond..
08/02 SUCAMPO PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, R..
08/02 SUCAMPO PHARMACEUTICALS, INC. (NASDA : SCMP) Files An 8-K Results of Operations ..
08/02 Sucampo Reports Second Quarter 2017 Financial Results
08/02 SUCAMPO PHARMACEUTICALS, INC. : Investor Network: Sucampo Pharmaceuticals, Inc. ..
07/19 SUCAMPO PHARMACEUTICALS, INC. (NASDA : SCMP) Files An 8-K Departure of Directors..
07/19 SUCAMPO PHARMACEUTICALS, INC. : Change in Directors or Principal Officers, Regul..
More news
News from SeekingAlpha
08/02 Sucampo Pharmaceuticals' (SCMP) CEO Peter Greenleaf on Q2 2017 Results - Earn..
08/02 Sucampo Pharma Q2 revenues up 15%; non-GAAP EPS up 17%; reiterates guidance
08/02 Sucampo beats by $0.01, beats on revenue
07/27 SUCAMPO : A Shift Toward Rare Diseases
05/23 Sucampo Pharmaceuticals (SCMP) Presents At Bank of America Merrill Lynch 2017..
Financials ($)
Sales 2017 235 M
EBIT 2017 99,4 M
Net income 2017 -91,5 M
Debt 2017 243 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018 11,02
EV / Sales 2017 3,07x
EV / Sales 2018 2,49x
Capitalization 477 M
Duration : Period :
Sucampo Pharmaceuticals, I Technical Analysis Chart | SCMP | US8649091068 | 4-Traders
Technical analysis trends SUCAMPO PHARMACEUTICALS, I
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 18,7 $
Spread / Average Target 82%
EPS Revisions
Peter S. Greenleaf Chairman & Chief Executive Officer
Peter P. Pfreundschuh Chief Financial Officer
Peter Lichtlen Chief Medical Officer
Peter Alec Kiener Chief Scientific Officer
Matthew Maxwell Donley EVP-Human Resources & Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN14.42%122 067